Japan's First Approval for Functional Claims of Rohto Group's Proprietary Material 'Licorice Extract Powder (Licocone®)'
MG Pharma, a Rohto Group member specializing in lipid metabolism, has achieved Japan's first acceptance of a functional food containing their proprietary Licorice Extract (Licocone®). The company continues to support global health challenges like obesity and lipid disorders through scientific innovation.
📋 Article Processing Timeline
- 📰 Published: April 21, 2026 at 11:00
- 🔍 Collected: April 21, 2026 at 11:31 (31 min after Published)
- 🤖 AI Analyzed: April 22, 2026 at 00:11 (12h 39m after Collected)
MG Pharma, a professional team in lipid metabolism research, focuses on supporting people's health regarding lifestyle diseases, particularly lipid metabolism disorders (neutral fat). Their work is anchored by the proprietary material 'Globin Peptide,' which was discovered from observations of weight loss in pigs, and their product 'Napple.' This issue of high neutral fat is becoming a significant concern not only in Japan but also internationally. MG Pharma will continue to challenge for 'Well-being' in collaboration with the Rohto Pharmaceutical Group and various external partners. Notably, a food product containing components derived from the Rohto Group's original material, 'Licorice Extract Powder (Licocone®),' has become the first of its kind to be accepted as a Food with Functional Claims in Japan.